On December 31, 2021 Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), an immuno-oncology
company developing innovative drug candidates for the prevention and treatment of cancer, reported a
corporate update on initiatives that were undertaken by the Company in 2021 (Press release, Helix BioPharma, DEC 31, 2021, View Source [SID1234608311]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Despite the challenges brought about by the COVID-19 pandemic, 2021 was a productive year for the Company.
During the second half of 2021, the Company initiated efforts to validate Helix and its lead clinical program with
external stakeholders to bring in an outside perspective to the company’s strategy and future, including but not limited to the following actions:
• In May of 2021, Helix engaged the consulting services of Dr. Christof Boehler, PhD, a seasoned biotechnology
scientist and entrepreneur to assess Helix and its assets. The outcome of this engagement was a positive outlook
on the potentials of L-DOS47, which has been demonstrated as safe in approximately 100 patients to date in the
Company’s Phase 1 clinical trials. Given the limitations of the current standard of care in addressing the high
unmet medical needs in oncology, the Company believes that the unique characteristics of L-DOS47 position
Helix as one of the leaders in the development of newer avenues like tumor microenvironments (change of tumor
pH), with an aim of improving the outcome of treatment of various malignancies with the use of L-DOS47 in
combination with immunotherapy and/or chemotherapy.
• In addition to Dr. Boehler’s assessment, Helix also retained the services of a highly experienced oncology
consultancy, Cello Healthcare ("Cello"), in August of 2021. A major aspect of this engagement included
interviews with certain key opinion leaders in the field to obtain their feedback and recommendations on the
Company’s L-DOS47 technology platform. The outcome of these interviews conducted by Cello both validated
the clinical work completed by Helix to date, and also helped the Company identify additional opportunities to
further strengthen and de-risk the Company’s clinical program, including optimal selection of patients for trials
(stratification) based on objective biomarkers, among other criteria. The Company anticipates that these activities
will facilitate strategic dialogue with potential market leaders in cancer treatment, and that the additional preclinical data obtained will further enhance the Company’s clinical program design.
• Finally, in September of 2021, Helix retained the consultancy services of Dr. Atul Deshpande, PhD, MBA, another
seasoned biotech executive who helped his previous employer, an immuno-oncology company, raise significant
funds from venture capital funds, and designed a focused strategy and execution plan in furtherance of the
Company’s public listing and significant concurrent financing. In his consulting role, Dr. Deshpande has been
tasked with implementing a refreshed corporate strategy and clinical plans to help the Company reach its goals.
Dr. Slawomir Majewski, Interim CEO and Director, states "We are hopeful that this kind of external validation
combined with internal expertise and experience will enable Helix to remain focused on the progression towards
developing unique therapies in the field of immuno-oncology for the treatment of cancer. We will continue to partner with these experienced advisors and experts in the field with an aim of enhancing the value of our platform and assets."
"Our clinical program remains our highest priority to ensure we deliver on a substantial data package that would
ultimately benefit patients and stakeholders alike. We await the final trial reports of the Phase I and II studies in lung
cancer in 2022. The other clinical trial in pancreatic cancer continues and we remain committed to this study. In
addition, in May 2021, we announced an agreement with Lind Global Macro Fund, LP, and subsequently closed a
first tranche financing for gross proceeds of $3,500,000. We are also working diligently to identify potential candidates to act as the Company’s permanent CEO," continued Dr. Majewski.